A regenerative stem cell phenotype marked by ANXA1 defines aggressive colorectal cancer biology
This study demonstrates that an aggressive colorectal cancer subtype characterized by ANXA1-enriched regenerative stem cells, distinct from LGR5+ homeostatic cells, is associated with specific molecular features, a macrophage-rich stromal microenvironment, and poor patient prognosis.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the human body, the lining of the intestine is a living, breathing surface that constantly renews itself. To keep this renewal going, the tissue relies on a small population of master cells known as stem cells. These are the architects of the gut, capable of dividing to create new tissue or repairing damage when the lining is injured. Scientists have long known that these stem cells are not all the same; they exist in different states depending on what the body needs. Some are quiet workers that maintain the daily rhythm of the gut, while others are emergency responders that spring into action when the tissue is damaged. In recent years, researchers have discovered that colorectal cancer often hijacks these stem cell programs. Instead of growing in a predictable way, cancer cells can switch between these different states, sometimes becoming more aggressive, more resistant to treatment, or better at spreading to other parts of the body. Understanding which state a tumor is in is crucial, because it could tell doctors how the cancer will behave and which treatments might work best.
A team of researchers set out to map these hidden states within thousands of colorectal cancer tumors to see if they could predict the course of the disease. They focused on two specific markers, or biological flags, that identify these different stem cell modes. One marker, called LGR5, identifies the steady-state cells that keep the gut running normally. The other, called ANXA1, identifies the regenerative cells that appear during injury or repair. The scientists wanted to know if the balance between these two types of cells inside a tumor could reveal something about its danger level. They analyzed tissue samples from 2,163 patients who had participated in a major clinical trial comparing different lengths of chemotherapy. Using advanced digital imaging and artificial intelligence, they looked at the tumors under a microscope to see exactly where these markers were located and how much of each was present.
The researchers found that the tumors were not uniform; they fell into distinct groups based on which stem cell type dominated. In some tumors, the steady-state LGR5 cells were most common, while in others, the regenerative ANXA1 cells took over. This difference was not random. The tumors dominated by the regenerative ANXA1 cells were linked to a specific, aggressive profile. These cancers were more likely to be found on the right side of the colon, to have specific genetic mutations, and to be surrounded by a dense network of supporting tissue and immune cells. Specifically, these aggressive tumors were filled with a high number of macrophages, a type of immune cell that can sometimes help tumors grow rather than fight them. In contrast, the tumors dominated by the steady-state LGR5 cells tended to have different genetic features and a less hostile environment.
The most significant discovery was that the balance between these two cell types could predict how the cancer would behave over time. Patients whose tumors were dominated by the regenerative ANXA1 cells had a higher risk of the cancer returning after treatment, even when the researchers accounted for other known risk factors like the size of the tumor or whether it had spread to lymph nodes. This pattern held true regardless of the specific molecular subtype of the cancer, suggesting that the stem cell state itself is a powerful indicator of danger. The study also looked at whether a longer course of chemotherapy helped these high-risk patients. The results showed that extending the treatment from three months to six months did not provide any extra benefit for the group with the aggressive, ANXA1-dominant tumors. This suggests that simply giving more of the same chemotherapy is not the solution for this specific type of cancer.
These findings offer a new way to look at colorectal cancer, moving beyond just the size of the tumor or its genetic mutations to consider the actual behavior of the cells inside it. By identifying tumors that are dominated by regenerative stem cells, doctors may be able to spot the most dangerous cases earlier. The research suggests that these aggressive tumors have a unique relationship with the immune system and the surrounding tissue that makes them harder to treat. While the study does not offer a new cure, it provides a clearer map of the enemy. It highlights that some cancers are not just growing faster, but are fundamentally different in how they adapt and survive. This knowledge could eventually help guide the development of new therapies that target these specific regenerative cells or the immune environment that supports them, offering hope for patients who currently face the highest risk of recurrence.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.